Financial Performance - Olo Inc. reported revenue of $80.68 million for the quarter ended March 2025, reflecting a year-over-year increase of 21.3% [1] - The earnings per share (EPS) for the quarter was $0.07, up from $0.05 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $77.52 million by 4.08% [1] - The company achieved an EPS surprise of 16.67%, with the consensus EPS estimate being $0.06 [1] Key Metrics - Average Revenue Per User (ARPU) was $911, surpassing the average estimate of $887.40 from two analysts [4] - The number of Ending Active Locations reached 88,000, compared to the estimated 86,950 by two analysts [4] - Revenue from the Platform segment was $79.23 million, exceeding the average estimate of $76.72 million from three analysts, representing a year-over-year change of 20.5% [4] - Revenue from Professional Services and Other was $1.45 million, significantly higher than the average estimate of $0.76 million, marking a year-over-year increase of 94.2% [4] - Non-GAAP Gross Profit from the Platform was $48.42 million, compared to the estimated $45.94 million from three analysts [4] Stock Performance - Olo's shares have returned 18.7% over the past month, outperforming the Zacks S&P 500 composite's return of 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Solventum (SOLV) reported revenue of $2.07 billion for the quarter ended March 2025, reflecting a year-over-year increase of 2.7% [1] - The company's EPS was $1.34, down from $2.08 in the same quarter last year, but exceeded the consensus estimate of $1.19, resulting in an EPS surprise of +12.61% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $2 billion, yielding a revenue surprise of +3.37% [1] Financial Performance Metrics - Net Sales in MedSurg reached $1.16 billion, exceeding the average estimate of $1.10 billion from three analysts [4] - Net Sales in Purification and Filtration were $242 million, slightly below the average estimate of $242.25 million [4] - Net Sales in Health Information Systems totaled $329 million, surpassing the average estimate of $319.96 million [4] - Net Sales in Dental Solutions amounted to $328 million, exceeding the average estimate of $325.61 million [4] - Operating Income in MedSurg was $206 million, below the average estimate of $229.10 million [4] - Operating Income in Purification and Filtration was $35 million, above the average estimate of $31.92 million [4] - Operating Income in Health Information Systems reached $109 million, exceeding the average estimate of $104.45 million [4] - Operating Income in Dental Solutions was $78 million, below the average estimate of $95.98 million [4] Stock Performance - Solventum's shares have returned -4.5% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Peloton (PTON) reported $624 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 13.1%. EPS of -$0.12 for the same period compares to -$0.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $619.71 million, representing a surprise of +0.69%. The company delivered an EPS surprise of -100.00%, with the consensus EPS estimate being -$0.06.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

In its upcoming report, Integral Ad Science (IAS) is predicted by Wall Street analysts to post quarterly earnings of $0.03 per share, reflecting an increase of 400% compared to the same period last year. Revenues are forecasted to be $129.66 million, representing a year-over-year increase of 13.2%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timefram ...

In its upcoming report, Landstar System (LSTR) is predicted by Wall Street analysts to post quarterly earnings of $0.92 per share, reflecting a decline of 30.3% compared to the same period last year. Revenues are forecasted to be $1.13 billion, representing a year-over-year decrease of 3.5%.The consensus EPS estimate for the quarter has been revised 2.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates d ...

For the quarter ended March 2025, Kemper (KMPR) reported revenue of $1.19 billion, up 5% over the same period last year. EPS came in at $1.65, compared to $1.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.23 billion, representing a surprise of -3.56%. The company delivered an EPS surprise of +11.49%, with the consensus EPS estimate being $1.48.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...

For the quarter ended March 2025, Nutrien (NTR) reported revenue of $5.1 billion, down 5.4% over the same period last year. EPS came in at $0.11, compared to $0.46 in the year-ago quarter.The reported revenue represents a surprise of -4.18% over the Zacks Consensus Estimate of $5.32 billion. With the consensus EPS estimate being $0.33, the EPS surprise was -66.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectati ...

Core Insights - Pan American Silver reported a revenue of $773.2 million for the quarter ended March 2025, marking a 28.6% increase year-over-year and a surprise of +10.99% over the Zacks Consensus Estimate of $696.62 million [1] - The company's EPS for the quarter was $0.42, significantly up from $0.01 in the same quarter last year, resulting in an EPS surprise of +121.05% compared to the consensus estimate of $0.19 [1] Financial Performance - The stock of Pan American Silver has returned +15.3% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change, and currently holds a Zacks Rank 2 (Buy) [3] - Key production metrics include: - Gold production: 182.2 Koz, slightly below the average estimate of 185.63 Koz [4] - Silver production: 5,003 Koz, exceeding the average estimate of 4,877.26 Koz [4] - La Colorada Operation produced 1.2 Koz of gold, above the average estimate of 0.66 Koz, and 1,389 Koz of silver, slightly above the average estimate of 1,357.67 Koz [4] - Huaron Operation produced 951 Koz of silver, exceeding the average estimate of 888.87 Koz [4] - San Vicente Operation produced 643 Koz of silver, above the average estimate of 629.11 Koz [4] - Dolores Operation produced 349 Koz of silver and 14 Koz of gold, both exceeding their respective average estimates [4] - Shahuindo Operation produced 29.5 Koz of gold, slightly below the average estimate of 30.43 Koz [4] - Timmins Operation produced 28.5 Koz of gold, below the average estimate of 30.31 Koz [4] Pricing Metrics - Average realized prices per ounce were: - Silver: $31.25, slightly below the average estimate of $32.08 [4] - Gold: $2,868, above the average estimate of $2,786.08 [4]

Core Insights - GoodRx Holdings, Inc. reported revenue of $202.97 million for Q1 2025, a year-over-year increase of 2.6% and an EPS of $0.09, compared to $0.08 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $202.59 million, resulting in a surprise of +0.19% [1] - The company did not deliver an EPS surprise, as the consensus EPS estimate was also $0.09 [1] Performance Metrics - GoodRx's shares returned +4.2% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the broader market in the near term [3] Key Company Metrics - Monthly Active Consumers: 6 million, below the estimated 7 million [4] - Subscription plans: 680 thousand, slightly below the estimated 685 thousand [4] - Revenue from Prescription transactions: $148.92 million, exceeding the estimate of $146.53 million, representing a +2.4% year-over-year change [4] - Revenue from Other sources: $4.38 million, below the estimate of $5.47 million, reflecting a year-over-year decline of -18.5% [4] - Revenue from Pharma manufacturer solutions: $28.65 million, slightly below the estimate of $29.90 million, but showing a +16.9% year-over-year increase [4] - Revenue from Subscription: $21.02 million, above the estimate of $20.79 million, but down -7% year-over-year [4]

Montrose Environmental (MEG) reported $177.83 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 14.5%. EPS of $0.07 for the same period compares to $0.16 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $167.97 million, representing a surprise of +5.87%. The company delivered an EPS surprise of +158.33%, with the consensus EPS estimate being -$0.12.While investors scrutinize revenue and earnings changes year-over-year and how they compa ...